Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolcanatide Bioactivity in Healthy Volunteers
NCT03300570Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in colorectal cancer (CRC) comparing Dolcanatide with Placebo (2 arms). Primary endpoint: Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels at 7 days. Started Jul 2018; status: completed.
02
Drugs
dolcanatide
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03300570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300570.